Abstract 【Objective】To investigate the efficacy of Niaoduqing combined with beraprost in the treatment of chronic glomerulonephritis(CGN) and its impact on patients' renal function. 【Methods】A total of 80 patients with CGN were randomly divided into two groups,with 40 cases in each group.Under routine intervention,patients in the control group were treated with beraprost,while patients in the observation group were additionally treated with Uremic Clearance,with a course of treatment of 90 days.The clinical efficacy,renal function indicators [24 hour urinary protein quantitation(24hUPro),serum creatinine(Scr),blood urea nitrogen(BUN),β2-microglobulin(β2-MG)] levels,and inflammatory factors [interleukin-6(IL-6),tumor necrosis factor-α(TNF-α),high-sensitivity C-reactive protein(hs-CRP)] levels,as well as adverse reactions,were observed and compared between the two groups. 【Results】The total effective rate in the observation group was significantly higher than that in the control group(P<0.05). After treatment,the levels of 24hUPro,Scr,BUN,β2-MG,IL-6,TNF-α,and hs-CRP in both groups decreased compared with those before treatment(P<0.05),and the levels of each index in the observation group were significantly lower than those in the control group(P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05). 【Conclusion】Niaoduqing combined with beraprost has significant efficacy in the treatment of CGN,which can effectively improve patients' renal function and reduce the level of inflammatory factors in the body. At the same time,it has high safety and is worthy of clinical application.
ZHU Lihong,LIU Huamei. The Efficacy of Niaoduqing Combined with Beraprost in the Treatment of Chronic Glomerulonephritis and its Impact on Renal Function[J]. JOURNAL OF CLINICAL RESEARCH, 2023, 40(11): 1628-1630.
[1] WU J,DUAN S W,YANG H T,et al. Efficacy and safety of Shenyankangfu Tablet,a Chinese patent medicine,for primary glomerulonephritis:A multicenter randomized controlled trial[J].J Int Med,2021,19(2):111-119.
[2] ANDREA F,PARIDE F,AVI R,et al. History of proliferative glomerulonephritis predicts end stage kidney disease in pure membranous lupus nephritis[J].Rheumatology,2021,61(6):2483-2493.
[3] WU T,MARAKKATH B,YE Y,et al. Curcumin attenuates both acute and chronic immune nephritis[J].Int J Molecular Sci,2020,21(5):1745.
[4] 刘童童,占永立,王宇阳,等.辛开苦降法治疗慢性肾小球肾炎初探[J].中国中医基础医学杂志,2020,26(4):455-457.
[5] 王海燕. 肾脏病学[M]. 北京:人民卫生出版社,2008:1256-1283.
[6] 中华中医药学会. 慢性肾小球肾炎诊疗指南[J].中国中医药现代远程教育,2011,9(9):129-132.
[7] JAYASUMANA C.Chronic interstitial nephritis in agricultural communities(CINAC) in sri lanka[J].Semin Nephrol,2019,39(3):278-283.
[8] 刘童童,占永立.基于脏腑风湿病机学说论治慢性肾小球肾炎[J].中医杂志,2019,60(20):1784-1786.
[9] 谷粒,胡耀,彭璇,等.肾炎康复片结合氯沙坦钾片治疗慢性肾小球肾炎临床疗效及对IL-1β、IL-1及VEGF水平的影响[J].中华中医药学刊,2021,39(5):213-216.
[10] WANG L,ZHAO L P,ZHU X Y,et al. GW29-e0354 Effect of beraprost on pulmonary hypertension due to left ventricular systolic dysfunction[J].J Am Coll Cardiol,2018,72(16):162.
[11] 陈嘉倩,陈艳琰,唐于平,等.大黄不同功效的古今用药规律分析[J].中草药,2019,50(6):1485-1492.
[12] 刘毓,刘鹏,韩晶雪,等.基于网络药理学大黄治疗慢性肾脏病机制研究[J].中华中医药学刊,2021,39(2):32-36.
[13] 孟宪悦,曲超,杨宇峰,等.基于网络药理学探讨黄芪-丹参药对治疗糖尿病肾病的作用机制[J].中华中医药学刊,2020,38(8):39-42.
2023, Vol. 40 
